Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Series C brings in $80mm for Relypsa

Executive Summary

Cardiovascular and renal therapeutics developer Relypsa Inc. has raised $80mm through its Series C venture round. There were 13 backers, including existing shareholders OrbiMed Advisors, 5AM Ventures, New Leaf Venture Partners, Sprout Group, Delphi Ventures, and Mediphase Venture Partners, and new investor Sibling Capital. Relypsa will use the funds for continued development, NDA submission, and eventual marketing of patiromer (RLY5016), a Phase III-ready non-absorbed oral potassium binder.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register